A Phase II Trial of Telisotuzumab Vedotin With Osimertinib for EGFR Mutated NSCLC With c-MET Overexpression That is Progressing on Osimertinib
This study is looking at a new treatment combination for patients with a specific type of lung cancer that has started to grow again while on standard therapy. By combining two different targeted therapies, doctors hope to better stop cancer cell growth and improve patient outcomes.
You may be eligible if you are 18 or older and have a type of lung cancer known as non-small cell lung cancer that has tested positive for a protein called c-MET. Your doctor must also confirm that your cancer has progressed while you were already taking a medication called osimertinib.
Participants will receive a combination of two targeted therapy drugs and undergo regular check-ups to monitor their health. These check-ups include routine blood tests, imaging scans like CTs or MRIs, and questionnaires to help researchers understand how you are feeling.
This study is currently recruiting new participants at a location in Los Angeles, California.
- 1The study tests if a new drug combination can help when standard treatment stops working.
- 2Participation involves taking targeted medications and having regular monitoring tests.
- 3This trial is for adults with a specific lung cancer protein called c-MET.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.